Brief: Athira Pharma To Present Additional Biomarker Data From Act-Ad Phase 2 Study Of Fosgonimeton At The 2022 Clinical Trials On Alzheimer’S Disease (Ctad) Conference
Athira Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Athira Pharma Inc Reports Quarterly Net Loss Of $20.2 Million, Or $0.53 Per Share
Athira Pharma Inc expected to post a loss of 63 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Alvotech, Verizon, Lyft, BofA
U.S. STOCKS ON THE MOVE-Gold miners, Protera, Sorrento
U.S. STOCKS ON THE MOVE-Bank of America, Archaea, Roblox
Athira Pharma rises on advancing Alzheimer's drug trial
Brief: Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study Of Fosgonimeton In Mild-To-Moderate Alzheimer’S Patients Following Independent, Unblinded Interim Analysis
Brief: Athira Pharma Provides Update On Plans For Ongoing Lift-Ad Clinical Study Of Fosgonimeton In Mild-To-Moderate Alzheimer’S Patients
Athira Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Athira Pharma Reports Q2 2022 Results
Athira Pharma Inc expected to post a loss of 64 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Bank Ozk, Bunge, Littelfuse
U.S. RESEARCH ROUNDUP-Alexandria Real Estate Equities, Beacon Roofing Supply, Snowflake
U.S. STOCKS ON THE MOVE-Moderna Inc, Nike Inc, Mustang Bio
U.S. STOCKS ON THE MOVE-Kraft Heinz Co, Coinbase, Altria Group
U.S. STOCKS ON THE MOVE-Athira Pharma, U.S. Well Services, Revlon
Athira Pharma falls as Alzheimer's drug candidate fails to meet study goal